Cat.#: ASSD-139
Description | Adenosine A1AR Affinity-Based Probe (AfBP) incubate with live cells or membrane fractions can selectively label the desired receptor in the presence of other proteins. AfBP acts as a partial agonist which is highly specific to the A1AR and binds covalently. Apparent pKi values at A1AR are 7.8 and 9.5 (following a 4h preincubation), where a Ki shift indicates a covalent mode of action. |
Size | 50 μg |
Applications | For use in confocal microscopy, SDS-PAGE and chemical proteomics profiling applications. |
Chemical Name | 4-((3-((6-Amino-4-(benzo[d][1,3]dioxol-5-yl)-3,5-dicyanopyridin-2-yl)thio)propyl)(prop-2-yn-1-yl)carbamoyl)benzenesulfonyl fluoride |
Molecule Weight | 577.6 |
Molecular formula | C27H20FN5O5S2 |
PubChem identifier | 167312224 |
Purity | >95% |
Solubility | Soluble in DMSO |
Storage | Store at -20° C |
Shipping | Shipped at 4°C |
Citation Guidance | If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. |
Cat.# | Name | Size | Price |
---|---|---|---|
ASSD-114 | Acridine Orange hydrochloride (AC114) | 50 mg | inquiry |
ASSD-199 | 4,7-Dioxaoctylenediamine N-[(Cyanine 3) Monofunctional Hexanoic Acid]-N′-[2-fluoro-4′-phosphophenylacetic Acid] Diamide (AC199) | 500 μg | inquiry |
ASSD-226 | Antifade Fluorescence Mounting Medium (hard set) (AC226) | 10 mL | inquiry |
ASSD-125 | Fluorescent D1 antagonist [SKF83566-green] (AC125) | 50 μg | inquiry |
ASSD-106 | Hoechst 33342 Staining Solution (10mg/ml) (AC106) | 5 mL, 10 mL | inquiry |
ASSD-182 | 9-(2-Carboxy-2-cyanovinyl)julolidine (AC182) | 5 mg | inquiry |
ASSD-142 | Methoxy-X04 (AC142) | 10 mg, 50 mg | inquiry |
ASSD-166 | FURA-2 (AC166) | 1 mg | inquiry |
ASSD-216 | K 114 (AC216) | 10 mg, 50 mg | inquiry |
ASSD-210 | 7-Amino-4-methyl-3-coumarinacetic acid N-succinimidyl ester (AC210) | 5 mg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.